<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637921</url>
  </required_header>
  <id_info>
    <org_study_id>284438/WP3</org_study_id>
    <nct_id>NCT02637921</nct_id>
  </id_info>
  <brief_title>Planetary Habitat Simulation: Bone Metabolism Studies</brief_title>
  <acronym>PlanHab</acronym>
  <official_title>Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jozef Stefan Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DLR German Aerospace Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kungliga Tekniska Hoegskolan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone losses are well known to occur in response to unloading (in microgravity or during
      immobilisation) and in patients with chronic obstructive airway disease (COPD). However, it
      is unknown whether there is an interactive effect between hypoxia and musculoskeletal
      unloading upon bone and mineral metabolism. Fourteen non-obese men, who are otherwise
      healthy, will undergo 3x 21-day interventions; normobaric normoxic bed rest (NBR; FiO2=21%),
      normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and
      normobaric hypoxic bed rest (HBR; FiO2=14%). The effects of hypoxia and bedrest on bone
      metabolism and phosphor-calcic homeostasis will be assessed (before and during each
      intervention, and 14 days after each intervention period) using venous blood sampling, 24hr
      urine collections, and peripheral quantitative computerized tomography (pQCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk of bone loss in response to immobilization and space flight is widely recognized,
      with such bone losses occurring predominantly in the legs. Loading forces in the lower
      extremities are typically low in space and during bed rest, but musculoskeletal loading
      countermeasures can prevent or reduce bone losses induced in these conditions. Although the
      primary origin may be of a mechanical nature, bone losses in astronauts and immobilized
      patients are likely to be modulated by the endocrine and the internal environment.

      Bone loss and osteoporosis is also prevalent in those with chronic obstructive pulmonary
      disease (COPD). The most discussed etiological factors for this condition include lack of
      physical activity, vitamin-D deficiency, hypogonadism, use of corticosteroids and smoking.
      However, COPD is associated with tissue hypoxemia and it is unclear whether hypoxia per se
      will affect bone turnover or metabolism.

      The protocol of the current study standardises potential confounding factors, such as
      physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the
      diet across all 3 interventions, and aims to extend our knowledge of the effects of hypoxia
      and bedrest on bone metabolism and phospho-calcic homeostasis.

      Fourteen non-obese men, who are otherwise healthy, will be recruited following medical and
      psychological screening. They will be invited to attend the Olympic Sport Centre, Planica,
      Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months.
      Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of
      intervention, and a recovery period (5 days), with a follow-up visit being carried out 14
      days after each intervention. The 3 interventions will be allocated in a randomized, cross
      over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic
      ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric
      hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised
      of foods commonly consumed in the Slovenian diet, will be applied during all campaigns.
      Targeted energy intakes will be calculated individually using a modified Benedict-Harris
      formula, with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and
      1.4 for the HAMB campaign, used to promote energy balance. Body mass will be monitored daily
      during the campaigns using a gurney incorporating load cells, and whole body composition will
      be determined before and immediately after each intervention using fan beam dual-emission
      X-ray absorptiometry. Macronutrient composition of the diet will be approximately 17%
      protein, 53% carbohydrate and 30% fat, with &gt;1.1g of protein per kg body weight provided per
      day, and daily salt (sodium chloride) intake being &lt;10g. Food will be provided in weighed
      portions and subjects will be encouraged to eat all food supplied. However, any food not
      eaten will be weighed and actual amount consumed recorded in a diet analysis programme.

      Participants will have bone mineral content assessed at 5 time points (before, 3 during and
      one after each intervention) using pQCT scans of the calf and thigh. Horizontal scans will be
      taken at 4%, 14%, 38%, and 66% of the tibia (assessed from its distal end), and at 4% and 33%
      of the femur. Twenty-four hour urine collections will be obtained before (2 time points),
      during (11 time points) and after (3 time points) each intervention, and will be assessed for
      urinary calcium and phosphate content, and for a marker of bone reabsorption (N-terminal
      telopeptide). In addition, early morning, fasting venous blood samples will also be taken
      before (2 time points), and during (5 time points) each intervention. These will be analysed
      for calcium, phosphate, bone specific alkaline phosphatase, parathyroid hormone,
      25-Hydroxyvitamin D, Procollagen-I-N-terminal propeptide and regulators of bone metabolism,
      (Dickkopf-related protein 1 and Sclerostin).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone mineral content, from baseline</measure>
    <time_frame>40 days</time_frame>
    <description>assessed before (day -5), on days 2, 10 and 21 of the intervention and at the 14-day follow-up visit (40 days after 1st measurement) using pQCT scans of the calf and thigh.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium concentration, from baseline</measure>
    <time_frame>30 days</time_frame>
    <description>assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 30 days after first measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary phosphate concentration, from baseline</measure>
    <time_frame>31 days</time_frame>
    <description>assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary N-terminal telopeptide concentration, from baseline</measure>
    <time_frame>31 days</time_frame>
    <description>assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum calcium concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum phosphate concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum bone specific alkaline phosphatase concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum parathyroid hormone concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum 25-Hydroxyvitamin D concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum Procollagen-I-N-terminal propeptide concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum Dickkopf-related protein 1 concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum Sclerostin concentration, from baseline</measure>
    <time_frame>26 days</time_frame>
    <description>assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hypoxia</condition>
  <condition>Bone Resorption</condition>
  <arm_group>
    <arm_group_label>Hypoxic ambulatory</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants ambulatory in normobaric hypoxia with standardised nutritional intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoxic Bed rest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are on bed rest in normobaric hypoxia with standardised nutritional intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxic bed rest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are on bed rest in normobaric normoxia with standardised nutritional intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxia</intervention_name>
    <description>21 days confinement in normobaric hypoxic (FiO2 = 14%)</description>
    <arm_group_label>Hypoxic ambulatory</arm_group_label>
    <arm_group_label>Hypoxic Bed rest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ambulatory</intervention_name>
    <description>Participants hava a standardized activity level throughout the intervention</description>
    <arm_group_label>Hypoxic ambulatory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normoxia</intervention_name>
    <description>21 days confinement in normobaric normoxic (FiO2 = 21%) environment</description>
    <arm_group_label>Normoxic bed rest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bed Rest</intervention_name>
    <description>Participants remain on supine bed rest throughout the intervention</description>
    <arm_group_label>Hypoxic Bed rest</arm_group_label>
    <arm_group_label>Normoxic bed rest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardised nutritional intake</intervention_name>
    <description>Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant</description>
    <arm_group_label>Hypoxic ambulatory</arm_group_label>
    <arm_group_label>Hypoxic Bed rest</arm_group_label>
    <arm_group_label>Normoxic bed rest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically and mentally healthy subjects

          -  Body mass index &lt; 25 kg/m2

          -  Height 158 - 190 cm

          -  Waist circumference &lt; 94 cm

          -  Volunteers that are able to declare their willingness to participate in the entire
             study

          -  Willing to be assigned randomly to the three groups

          -  Successfully passing the psychological and medical screening

          -  competent to sign informed consent

          -  Slovenian social insurance

          -  English language fluency

        Exclusion Criteria:

          -  Medication required that may interfere with the interpretation of the results

          -  Bone mineral density (as measured by DEXA) more than 1.5 standard deviations &lt; t score

          -  Recent sub-standard nutritional status

          -  Family history of thrombosis or positive response in thrombosis screening procedure.

        (Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive
        protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor
        II)

          -  History of: thyroid dysfunction, renal stones, diabetes, allergies, hypertension,
             hypocalcemia, uric acidaemia, lipidaemia, or hyperhomocysteinaemia

          -  Gastro-esophageal reflux disease or renal function disorder, Hiatus hernia

          -  History of medical illness

          -  Smoker within six months prior to the start of the study

          -  Abuse of drugs, medicine or alcohol

          -  Participation in another study up to two months before study onset

          -  No signed consent form before the onset of the experiment

          -  Blood donors in the past three months before the onset of the experiment

          -  Vegetarian and Vegans

          -  Migraines

          -  History of orthostatic intolerance

          -  History of vestibular disorders

          -  Claustrophobia

          -  metallic implants, osteosynthesis material

          -  Chronic back pain
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Mekjavic, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jozef Stefan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JÃ¶rn Rittweger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Aerospace Center (DLR)</affiliation>
  </overall_official>
  <link>
    <url>http://www.planhab.com</url>
    <description>project web site</description>
  </link>
  <results_reference>
    <citation>Rittweger J, Debevec T, Frings-Meuthen P, Lau P, Mittag U, Ganse B, Ferstl PG, Simpson EJ, Macdonald IA, Eiken O, Mekjavic IB. On the combined effects of normobaric hypoxia and bed rest upon bone and mineral metabolism: Results from the PlanHab study. Bone. 2016 Oct;91:130-8. doi: 10.1016/j.bone.2016.07.013. Epub 2016 Jul 18.</citation>
    <PMID>27443510</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nottingham</investigator_affiliation>
    <investigator_full_name>Elizabeth Simpson</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>bed rest</keyword>
  <keyword>bone metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Bone Resorption</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

